RxDoctor Payments Data

Sheri Moonan

Critical Care Medicine · Oak Lawn, ILNPI 1831623636

Payments from drug & device makers

$2,093in general payments, 2019–2025

Across 86 payments — averaging $24.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$661
  • AstraZeneca$461
  • Boehringer Ingelheim$358
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$103
  • Alnylam Pharmaceuticals Inc.$102
  • Lexicon Pharmaceuticals, Inc.$78
  • plus $328 from 7 others

What the payments were for

  • Food & beverage$2,06098%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,093 in reported general payments places this provider in the 75th percentile of 281 critical care medicine providers in Illinois.

See all critical care medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$8,574
Medicare patients
91
Services billed
131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten25$208,829
EntrestoSacubitril/Valsartan145$146,785
JardianceEmpagliflozin84$84,879
FarxigaDapagliflozin Propanediol50$46,634
Torsemide153$5,140
Potassium Chloride120$2,138
Metoprolol Succinate91$1,306
Spironolactone142$1,028
Carvedilol81$955
Furosemide112$586
Klor-Con M20Potassium Chloride15$409
Hydralazine Hcl40$406
Metolazone14$204
Losartan Potassium20$171
Digoxin13$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$70$208,82925 claims
Boehringer IngelheimJardiance$358$84,87984 claims
AstraZenecaFarxiga$461$46,63450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 281 critical care medicine providers in Illinois.

Other critical care medicine in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →